TrialBreast (Edinburgh, Scotland)2026

Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.

L Gianni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.